Russian drug manufacturer Generium Pharmaceutical, which specializes in orphan drugs, announced yesterday that it has received Russian marketing approval for its biosimilar eculizumab, referencing Soliris, the most expensive orphan drug in Russia.
Russian drug manufacturer Generium Pharmaceutical, which specializes in orphan drugs, announced yesterday that it has received Russian marketing approval for its biosimilar eculizumab, referencing Soliris, the most expensive orphan drug in Russia.
The biosimilar was authorized for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), which is a rare and life-threatening disease of the blood characterized by destruction of red blood cells by the complement system, and atypical hemolytic uremic syndrome (aHUS), which is an extremely rare, life-threatening, and progressive condition caused by the uncontrolled activation of the complement system.
“The joint efforts of Russian, US, and Swiss scientists have made it possible to achieve significant progress in the development of high-tech medicines for the treatment of rare diseases such as a PNH and aHUS, with the economic benefits of local production,” Dmitriy Kudlay, chief executive officer of Generium, said in a statement announcing the product’s approval.
While Generium is the first to gain approval for its biosimilar, it is by no means the only Russian drug developer with an interest in eculizumab; Biocad recently announced that it has begun clinical studies for its own biosimilar eculizumab candidate referencing Soliris.
Biocon’s study of the eculizumab biosimilar in patients with PNH, marking a foray into ultrarare diseases, is a new direction for the Russian biosimilar developer; thus far, Biocad has focused on the development of more widely used biosimilars, such as filgrastim, bevacizumab, trastuzumab, infliximab, and adalimumab.
Increasingly, developers see ultrarare diseases as viable markets for their biosimilars, due in part to the fact that patients with rare diseases are taking even the highest-priced drugs at increasing volumes; Alexion, which makes the reference eculizumab product, recently revealed that its sales volume for the ultra—high-cost drug had increased by 24% in 2018 versus 2017, driven in part by its recently granted indication for the treatment of the rare disease myasthenia gravis. Alexion is also seeking another new indication for the innovator product in another rare disease, anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.